home

LATEST ONCOPRESCRIBE UPDATES

• De-escalated Neoadjuvant Dual Anti-HER2 Blockade and Survival Outcomes in Early Breast Cancer

• KEYTRUDA® Versus ADCETRIS® in Relapsed or Refractory Classical Hodgkin Lymphoma

• Long Term Survival Benefit in Advanced Melanoma with OPDIVO® plus YERVOY®

• Circulating Tumor DNA as a Biomarker in Advanced Colorectal Cancer

SHOW MORE

FDA
Approvals

Meeting
Updates

Hem/Onc
Updates

Symptom
Management

NEW REGIMENS ADDED

Research Regimens

• Single Agent PEMAZYRE® - for Cholangiocarcinoma

• PARAPLATIN® and VEPESID® with IMFINZI® - for Small Cell Lung Cancer

• IMFINZI® Maintenance - Small Cell Lung Cancer

• TECENTRIQ® and ABRAXANE® - for Breast Cancer

• IDHIFA® - for Acute Myeloid Leukemia

Curbside Consultation

Breast Cancer Special Issue

Immuno-Oncology

Precision Oncology

• COVID-19 Associated Coagulopathy: Diagnosis and Management

• Dual Inhibition Improves Outcomes for Patients with BRAF-Mutated Colorectal Tumors

• Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

• FDA Approves ENDARI®, A New Treatment for Sickle Cell Disease

SHOW MORE